127 related articles for article (PubMed ID: 34533098)
1. Long non-coding RNAs as a predictive markers of group 3 medulloblastomas.
Mutlu M; Tekin C; Ak Aksoy S; Taskapilioglu MO; Kaya S; Balcin RN; Ocak PE; Kocaeli H; Bekar A; Tolunay S; Tunca B
Neurol Res; 2022 Mar; 44(3):232-241. PubMed ID: 34533098
[TBL] [Abstract][Full Text] [Related]
2. In silico analysis of long non-coding RNAs in medulloblastoma and its subgroups.
Joshi P; Jallo G; Perera RJ
Neurobiol Dis; 2020 Jul; 141():104873. PubMed ID: 32320737
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA profiling of pediatric Medulloblastoma.
Kesherwani V; Shukla M; Coulter DW; Sharp JG; Joshi SS; Chaturvedi NK
BMC Med Genomics; 2020 Jun; 13(1):87. PubMed ID: 32591022
[TBL] [Abstract][Full Text] [Related]
4. Non-coding RNAs in Brain Tumors, the Contribution of lncRNAs, circRNAs, and snoRNAs to Cancer Development-Their Diagnostic and Therapeutic Potential.
Latowska J; Grabowska A; Zarębska Ż; Kuczyński K; Kuczyńska B; Rolle K
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977537
[TBL] [Abstract][Full Text] [Related]
5. Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis.
Łastowska M; Trubicka J; Niemira M; Paczkowska-Abdulsalam M; Karkucińska-Więckowska A; Kaleta M; Drogosiewicz M; Perek-Polnik M; Krętowski A; Cukrowska B; Grajkowska W; Dembowska-Bagińska B; Matyja E
J Neurooncol; 2018 Jun; 138(2):231-240. PubMed ID: 29427151
[TBL] [Abstract][Full Text] [Related]
6. Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy.
Blüml S; Margol AS; Sposto R; Kennedy RJ; Robison NJ; Vali M; Hung LT; Muthugounder S; Finlay JL; Erdreich-Epstein A; Gilles FH; Judkins AR; Krieger MD; Dhall G; Nelson MD; Asgharzadeh S
Neuro Oncol; 2016 Jan; 18(1):126-31. PubMed ID: 26254476
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase IIβ immunoreactivity (IR) co-localizes with neuronal marker-IR but not glial fibrillary acidic protein-IR in GLI3-positive medulloblastomas: an immunohistochemical analysis of 124 medulloblastomas from the Japan Children's Cancer Group.
Miyahara H; Natsumeda M; Kanemura Y; Yamasaki K; Riku Y; Akagi A; Oohashi W; Shofuda T; Yoshioka E; Sato Y; Taga T; Naruke Y; Ando R; Hasegawa D; Yoshida M; Sakaida T; Okada N; Watanabe H; Ozeki M; Arakawa Y; Yoshimura J; Fujii Y; Suenobu S; Ihara K; Hara J; Kakita A; Yoshida M; Iwasaki Y
Brain Tumor Pathol; 2021 Apr; 38(2):109-121. PubMed ID: 33704596
[TBL] [Abstract][Full Text] [Related]
8. Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas.
Kunder R; Jalali R; Sridhar E; Moiyadi A; Goel N; Goel A; Gupta T; Krishnatry R; Kannan S; Kurkure P; Deopujari C; Shetty P; Biyani N; Korshunov A; Pfister SM; Northcott PA; Shirsat NV
Neuro Oncol; 2013 Dec; 15(12):1644-51. PubMed ID: 24203893
[TBL] [Abstract][Full Text] [Related]
9. [Molecular subgrouping and characterization analysis of medulloblastomas in a cohort of Japanese patients].
Wataya T; Hamasaki M; Taylor MD
No Shinkei Geka; 2015 Feb; 43(2):117-25. PubMed ID: 25672552
[TBL] [Abstract][Full Text] [Related]
10. CIC, a gene involved in cerebellar development and ErbB signaling, is significantly expressed in medulloblastomas.
Lee CJ; Chan WI; Scotting PJ
J Neurooncol; 2005 Jun; 73(2):101-8. PubMed ID: 15981098
[TBL] [Abstract][Full Text] [Related]
11. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.
Ellison DW; Dalton J; Kocak M; Nicholson SL; Fraga C; Neale G; Kenney AM; Brat DJ; Perry A; Yong WH; Taylor RE; Bailey S; Clifford SC; Gilbertson RJ
Acta Neuropathol; 2011 Mar; 121(3):381-96. PubMed ID: 21267586
[TBL] [Abstract][Full Text] [Related]
12. Cytogenetic prognostication within medulloblastoma subgroups.
Shih DJ; Northcott PA; Remke M; Korshunov A; Ramaswamy V; Kool M; Luu B; Yao Y; Wang X; Dubuc AM; Garzia L; Peacock J; Mack SC; Wu X; Rolider A; Morrissy AS; Cavalli FM; Jones DT; Zitterbart K; Faria CC; Schüller U; Kren L; Kumabe T; Tominaga T; Shin Ra Y; Garami M; Hauser P; Chan JA; Robinson S; Bognár L; Klekner A; Saad AG; Liau LM; Albrecht S; Fontebasso A; Cinalli G; De Antonellis P; Zollo M; Cooper MK; Thompson RC; Bailey S; Lindsey JC; Di Rocco C; Massimi L; Michiels EM; Scherer SW; Phillips JJ; Gupta N; Fan X; Muraszko KM; Vibhakar R; Eberhart CG; Fouladi M; Lach B; Jung S; Wechsler-Reya RJ; Fèvre-Montange M; Jouvet A; Jabado N; Pollack IF; Weiss WA; Lee JY; Cho BK; Kim SK; Wang KC; Leonard JR; Rubin JB; de Torres C; Lavarino C; Mora J; Cho YJ; Tabori U; Olson JM; Gajjar A; Packer RJ; Rutkowski S; Pomeroy SL; French PJ; Kloosterhof NK; Kros JM; Van Meir EG; Clifford SC; Bourdeaut F; Delattre O; Doz FF; Hawkins CE; Malkin D; Grajkowska WA; Perek-Polnik M; Bouffet E; Rutka JT; Pfister SM; Taylor MD
J Clin Oncol; 2014 Mar; 32(9):886-96. PubMed ID: 24493713
[TBL] [Abstract][Full Text] [Related]
13. Various components of the insulin-like growth factor system in tumor tissue, cerebrospinal fluid and peripheral blood of pediatric medulloblastoma and ependymoma patients.
de Bont JM; van Doorn J; Reddingius RE; Graat GH; Passier MM; den Boer ML; Pieters R
Int J Cancer; 2008 Aug; 123(3):594-600. PubMed ID: 18478565
[TBL] [Abstract][Full Text] [Related]
14. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.
Remke M; Hielscher T; Korshunov A; Northcott PA; Bender S; Kool M; Westermann F; Benner A; Cin H; Ryzhova M; Sturm D; Witt H; Haag D; Toedt G; Wittmann A; Schöttler A; von Bueren AO; von Deimling A; Rutkowski S; Scheurlen W; Kulozik AE; Taylor MD; Lichter P; Pfister SM
J Clin Oncol; 2011 Oct; 29(29):3852-61. PubMed ID: 21911727
[TBL] [Abstract][Full Text] [Related]
15. MRI surrogates for molecular subgroups of medulloblastoma.
Perreault S; Ramaswamy V; Achrol AS; Chao K; Liu TT; Shih D; Remke M; Schubert S; Bouffet E; Fisher PG; Partap S; Vogel H; Taylor MD; Cho YJ; Yeom KW
AJNR Am J Neuroradiol; 2014 Jul; 35(7):1263-9. PubMed ID: 24831600
[TBL] [Abstract][Full Text] [Related]
16. Medulloblastoma.
Millard NE; De Braganca KC
J Child Neurol; 2016 Oct; 31(12):1341-53. PubMed ID: 26336203
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of miR-204 expression defines a highly aggressive subset of Group 3/Group 4 medulloblastomas.
Bharambe HS; Paul R; Panwalkar P; Jalali R; Sridhar E; Gupta T; Moiyadi A; Shetty P; Kazi S; Deogharkar A; Masurkar S; Yogi K; Kunder R; Gadewal N; Goel A; Goel N; Chinnaswamy G; Ramaswamy V; Shirsat NV
Acta Neuropathol Commun; 2019 Apr; 7(1):52. PubMed ID: 30944042
[TBL] [Abstract][Full Text] [Related]
18. Thioredoxin System Protein Expression Is Associated with Poor Clinical Outcome in Adult and Paediatric Gliomas and Medulloblastomas.
Yao A; Storr SJ; Al-Hadyan K; Rahman R; Smith S; Grundy R; Paine S; Martin SG
Mol Neurobiol; 2020 Jul; 57(7):2889-2901. PubMed ID: 32418115
[TBL] [Abstract][Full Text] [Related]
19. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-21 and long non-coding RNA MALAT1 are overexpressed markers in medullary thyroid carcinoma.
Chu YH; Hardin H; Schneider DF; Chen H; Lloyd RV
Exp Mol Pathol; 2017 Oct; 103(2):229-236. PubMed ID: 29107050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
